ストックスクリーナーアプリを入手
15.47
3.06%
0.46
アフターアワーズ：
15.47
Amylyx Pharmaceuticals Inc (AMLX) 最新ニュース
Amylyx Pharmaceuticals: Back From The Dead (NASDAQ:AMLX) - Seeking Alpha
FY2030 Earnings Estimate for AMLX Issued By HC Wainwright - MarketBeat
Is Amylyx Pharmaceuticals Inc still a buy after recent gainsJuly 2025 Chart Watch & Entry Point Strategy Guides - baoquankhu1.vn
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Amylyx nominates AMX0318 as long-acting GLP-1 candidate for rare endocrine disorders - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 4.5%What's Next? - MarketBeat
How Investors May Respond To Gubra (CPSE:GUBRA) Securing Amylyx GLP-1 Milestones And Royalty Upside - Yahoo Finance
Amylyx Pharmaceuticals stock hits 52-week high at $16.96 By Investing.com - Investing.com Nigeria
Amylyx Pharma Hits New HighDelivers Over 160% Gain In 7 Months - Nasdaq
Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 52-Week HighTime to Buy? - MarketBeat
January 2027 Options Now Available For Amylyx Pharmaceuticals (AMLX) - Nasdaq
Amylyx Pharmaceuticals stock hits 52-week high at $16.96 - Investing.com
Amylyx Pharmaceuticals (AMLX) Valuation After AMX0318 Rare Disease Pipeline Update - simplywall.st
Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock - Investing.com Australia
Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock By Investing.com - Investing.com India
Amylyx pharma co-CEO Cohen sells $1.87m in shares By Investing.com - Investing.com India
Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Sells $1,850,862.87 in Stock - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Sells $27,300.42 in Stock - MarketBeat
Amylyx pharma co-CEO Cohen sells $1.87m in shares - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading 11.7% HigherHere's What Happened - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 8.85% on Jan 20 - GuruFocus
EV Market: Is Amylyx Pharmaceuticals Inc stock a good pick for beginnersWeekly Stock Recap & Pattern Based Trade Signal System - baoquankhu1.vn
Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders - Finviz
More Money In The Bank For Amylyx Pharmaceuticals Insiders Who Divested US$2.0m - 富途牛牛
Amylyx Pharmaceuticals Inc (AMLX) Trading 3.18% Higher on Jan 16 - GuruFocus
9 Overlooked Growth Stocks to Buy - Insider Monkey
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Up 6.5%What's Next? - MarketBeat
Insider Trends: Will Amylyx Pharmaceuticals Inc. stock sustain high P E ratios2025 Trading Recap & Fast Moving Stock Watchlists - Bộ Nội Vụ
Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage - Yahoo Finance
Amylyx Pharmaceuticals (AMLX) announces the selection of AMX0318 as development candidate for PBH and other rare diseases - MSN
Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases - Finviz
Is Amylyx Pharmaceuticals Inc. stock trading at a premium valuation2025 Technical Overview & Short-Term Trading Alerts - ulpravda.ru
Buy Rating on Amylyx: Avexitide’s High Unmet Need, Strong PBH Opportunity, and Clear Phase III Catalyst Support Upside - TipRanks
How Amylyx Pharmaceuticals’ (AMLX) Move Into GLP-1 Rare Diseases Has Changed Its Investment Story - Sahm
Amylyx selects AMX-0318 as development candidate - BioWorld MedTech
Amylyx selects AMX0318 as development candidate for PBH - Yahoo Finance
Is Amylyx Pharmaceuticals Inc. stock recession proofJuly 2025 Reactions & Stepwise Entry/Exit Trade Alerts - Улправда
Why Amylyx Pharmaceuticals Inc. stock could outperform in 2025Treasury Yields & Community Consensus Stock Picks - Улправда
Top Amylyx Executives Quietly Cash Out in Coordinated Stock Moves - TipRanks
James Frates Sells 3,326 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
Mizuho reiterates Outperform rating on Amylyx stock, cites GLP-1 program By Investing.com - Investing.com Nigeria
Mizuho reiterates Outperform rating on Amylyx stock, cites GLP-1 program - Investing.com Australia
US company unveils candidate for Gubra partnership - medwatch.com
Amylyx Advances AMX0318 as New Rare-Disease Candidate - TipRanks
Amylyx Pharmaceuticals, Inc. Announces Development of AMX0318 - TradingView — Track All Markets
0.51%
9.76%
大文字化:
|
ボリューム (24 時間):